Coke Florida Names Jamaal Medley as Vice President, Field Franchise Operations
BUSINESS WIRE)--Coca-Cola Beverages Florida, LLC (Coke Florida) announced Jamaal Medley has been promoted to Vice President, Field Franchise Operations.
Coke Florida's 47 Florida county footprint operations span across 18 territories. Jamaal will provide strategic and operational leadership to the local territory general managers who are responsible for overseeing the integration of sales, manufacturing, distribution, warehouse, and merchandising operations to improve local business outcomes. The territory leaders also lead engagement with the company's 5,000 plus associates and play a critical role in partnering with communities.
Medley has more than eighteen years of experience in the Coca-Cola System and joins the Senior Leadership Team from his current role as Coke Florida's Territory General Manager for the Jacksonville territory, which includes manufacturing, sales, and distribution operations. Joining the company in 2016, he has held positions as Quality Assurance Manager, Production Manager, and Plant Manager. Jamaal Medley holds undergraduate and graduate degrees in Business Administration from Strayer University.
'Jamaal has been a key leader in the success of Coke Florida's operations in the northern portion of the state," said Andy Hill, Senior Vice President, Chief Customer and Commercial Officer for Coke Florida. 'His experience across the system positions him to move into this role and his leadership will enable strong execution and continued growth in the Florida marketplace.'
Coke Florida has a commitment to the communities across its footprint and Medley supports this commitment through his roles as a Board Member for the Boys and Girls Club Northeast Florida, Board of Directors for the Jacksonville Chamber and the Advisory Boards for Teach for America and Saint John County Transportation and Logistics Academy.
Medley added, 'Having joined Coke Florida in 2016 when the newly formed company started operations, I am honored to step into this new role. I look forward to my role as a leader in the continued growth and strong performance of our company."
Consistent with Coke Florida's approach to leader succession, Medley moves into this role as Scott McLaughlin transitions from the Company.
About Coca-Cola Beverages Florida, LLC
Coca-Cola Beverages Florida, LLC (Coke Florida) is the sixth largest Coca-Cola bottler in the United States. Coke Florida markets, sells, manufactures, distributes, and merchandises products of The Coca-Cola Company in an exclusive territory that covers over 21 million consumers across 47 Florida counties that includes the Miami, Tampa, Orlando, and Jacksonville metropolitan areas. The company employs over 5,000 associates and has four GreenCircle certified manufacturing facilities and eighteen sales and distribution centers. Founded in 2015 and headquartered in Tampa, Coke Florida is the one of the largest Black-owned businesses in the United States and is Minority Business Enterprise (MBE) certified. Coke Florida has been recognized as a US Best Managed Company for four consecutive years by Deloitte-Private and The Wall Street Journal, making the company a Gold Standard Winner in 2025. To learn more, visit www.cokeflorida.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
QPS Celebrates 30th Anniversary
Newark, Del., United States: QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS is now recognized as a global leader in contract research. Over the past 30 years, the company has grown from a single office in Delaware, USA to a widely respected, global, full-service CRO with 8 locations spread across the US, EU, Asia, India and Australia, a clinical trial network of over 700 sites and an increased focus on leveraging the power of AI to accelerate clinical trials. This press release features multimedia. View the full release here: Dr. Benjamin Chien founder and CEO of QPS Holdings, LLC. Over the years, QPS has grown from a small molecule bioanalysis shop of three people to a global CRO with more than 1,200 employees. '30 years is a major milestone for QPS and I couldn't be more proud of the hard-working and innovative people who choose to work at QPS. They are the backbone of the company, and I am very grateful for their valuable contributions,' said founder and CEO of QPS, Dr. Benjamin Chien. 'Through QPS, the pharmaceutical and biotechnology industries have access to dedicated, focused scientific expertise across the drug development spectrum. In facilities around the world, QPS has assembled best-in-class instruments, platforms, people and processes required to conduct the studies necessary to support client drug discovery and development programs focused on obesity, type 2 diabetes, oncology, CNS diseases, cell and gene therapy, and more,' said Dr. Chien. Since its humble beginnings, QPS has expanded its service options, to include pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs, cell therapy products, clinical trials, central lab services, and a full range of clinical research services. QPS is known for high-quality data, technical expertise, delivery of promised study timelines, collaborative solutions, and customer-focused strategies. Going forward, QPS plans to continue delivering custom-built research services that accelerate pharmaceutical breakthroughs across the globe. ABOUT QPS HOLDINGS, LLC QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and Australia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs and cell therapy products, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit or email [email protected] . View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Business Insider
5 hours ago
- Business Insider
What a Costco Recall Means for Coca-Cola Stock (KO)
A new recall has been issued for a Coca-Cola (KO) product sold in select Costco (COST) stores. This recall affects Topo Chico Mineral Water and was issued due to a possible Pseudomonas aeruginosa contamination. Confident Investing Starts Here: Pseudomonas aeruginosa occurs in natural environments, such as in water and soil. It isn't largely dangerous to healthy individuals. However, those with compromised immune systems might suffer negative effects from its presence in Topo Chico Mineral Water. This could include infections of the blood, lungs, urinary tract, skin, eyes, ears, and other parts of the body. Items included in the Coca-Cola recall include 18-packs of 16.9-ounce Topo Chico Mineral Water with a lot code of #13A2541. These were sold at Costco stores in Texas and Louisiana from May 20, 2025, to May 29, 2025. Consumers will note that no other Topo Chico Mineral Water products are included in this recall. Those who have purchased affected products can return them to Costco for a refund. How Does This Recall Affect KO Stock? Considering the small size and low risk of the recall, Coca-Cola investors don't appear overly worried about it. The company's stock was up 0.59% as of Wednesday afternoon and has rallied 15.83% year-to-date. The shares have seen strong performance in 2025, despite ongoing inflation, increased interest rates, trade war updates, and new tariffs. These issues have weighed down stock markets this year. Is Coca-Cola Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Coca-Cola is Moderate Buy, based on 15 Buy and one Hold rating over the past three months. With that comes an average KO stock price target of $79.33, representing a potential 79.33% upside for the shares.
Yahoo
9 hours ago
- Yahoo
SDRS investments tick up amid volatile markets
PIERRE, S.D. (KELO) — The South Dakota Retirement System's investments have rebounded a bit. The estimated return, covering the 11 months through May 31, was 3.2 to 3.7%, senior portfolio manager Darci Haug told SDRS trustees on Wednesday. Man identified in fatal Monday I-90 crash The annual target, however, is 6.5%. Whether that can be reached by June 30 isn't known. 'We aren't keeping up with the markets because of our conservative positioning,' portfolio manager Danielle Mourer explained. The South Dakota Investment Council oversees the SDRS portfolio. The council over the long term has taken a contrarian approach, holding larger amounts of cash at times when the market is, in the council's estimation, overpriced. That's how the council currently sees the markets. Nonetheless, being back in the black was an improvement over the April 9 report to the SDRS trustees. On that date, SDRS investments as a whole were down between 3 and 3.5%. The very next day, they had regained some of that lost value and were down 0.5 to 1%. Jarrod Edelen, another of the portfolio's managers, said earnings by different sectors have been volatile of late and varied widely. Technology investments such as computer chips were recently up 27% while energy investments overall were down 7%, he said. The fair market value of SDRS investments was $15 billion as of May 31, Haug said. How the SDRS investments fare year to year largely determines the size of the annual cost of living adjustment paid the following year to the system's retirees and other beneficiaries. SDRS senior actuary Doug Fiddler told the board that the COLA taking effect on July 1, 2025, will be 1.71%. That was calculated using the third quarter 2024 inflation rate of 2.49%. Fiddler estimated that a 3.5% annual return for fiscal 2025 would result in a COLA of approximately 1.4% taking effect on July 1, 2026. He said benefit payments to approximately 80% of SDRS retirees have been falling short of keeping up inflation by about 10%. Fiddler presented a chart showing the S&P 500 has been in a volatile stretch lately, dropping about 20% in April and gradually rebounding since then. Fiddler said that he had planned to brief the trustees on corrective actions that might be necessary when the SDRS investments were in the red for the year. But he changed his mind after seeing the number get back into the black. SDRS executive director Travis Almond spoke about market volatility to the board after Fiddler's presentation. 'So who knows how the end of this fiscal year lands,' Almond said. He suggested that the trustees keep themselves familiar with the corrections plan. 'I have no doubt we're going to have that conversation. It's a question of when,' Almond said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
